VSports最新版本 - Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site VSports app下载. .

Https

The site is secure V体育官网. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. .

Observational Study
. 2020 Sep;41(9):1469-1487.
doi: 10.1002/humu.24056. Epub 2020 Jun 24.

ASAH1 pathogenic variants associated with acid ceramidase deficiency: Farber disease and spinal muscular atrophy with progressive myoclonic epilepsy

Affiliations
Observational Study

ASAH1 pathogenic variants associated with acid ceramidase deficiency: Farber disease and spinal muscular atrophy with progressive myoclonic epilepsy (VSports手机版)

Sarah H Elsea et al. Hum Mutat. 2020 Sep.

Abstract

Farber disease and spinal muscular atrophy with progressive myoclonic epilepsy are a spectrum of rare lysosomal storage disorders characterized by acid ceramidase deficiency (ACD), resulting from pathogenic variants in N-acylsphingosine amidohydrolase 1 (ASAH1). Other than simple listings provided in literature reviews, a curated, comprehensive list of ASAH1 mutations associated with ACD clinical phenotypes has not yet been published. This publication includes mutations in ASAH1 collected through the Observational and Cross-Sectional Cohort Study of the Natural History and Phenotypic Spectrum of Farber Disease (NHS), ClinicalTrials. gov identifier NCT03233841, in combination with an up-to-date curated list of published mutations. The NHS is the first to collect retrospective and prospective data on living and deceased patients with ACD presenting as Farber disease, who had or had not undergone hematopoietic stem cell transplantation. Forty-five patients representing the known clinical spectrum of Farber disease (living patients aged 1-28 years) were enrolled. The curation of known ASAH1 pathogenic variants using a single reference transcript includes 10 previously unpublished from the NHS and 63 that were previously reported. The publication of ASAH1 variants will be greatly beneficial to patients undergoing genetic testing in the future by providing a significantly expanded reference list of disease-causing variants. VSports手机版.

Keywords: ASAH1; Farber disease; N-acylsphingosine amidohydrolase 1; acid ceramidase; acid ceramidase deficiency (ACD); lysosomal storage disorder; spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME) V体育安卓版. .

PubMed Disclaimer

References

REFERENCES

    1. Alayoubi, A. M., Wang, J. C., Au, B. C., Carpentier, S., Garcia, V., Dworski, S., … Medin, J. A. (2013). Systemic ceramide accumulation leads to severe and varied pathological consequences. EMBO Molecular Medicine, 5, 827-842.
    1. Alves, M. Q., Le Trionnaire, E., Ribeiro, I., Carpentier, S., Harzer, K., Levade, T., & Ribeiro, M. G. (2013). Molecular basis of acid ceramidase deficiency in a neonatal form of Farber disease: Identification of the first large deletion in ASAH1 gene. Molecular Genetics and Metabolism, 109, 276-281.
    1. Antonarakis, S. E., Valle, D., Moser, H. W., Moser, A., Qualman, S. J., & Zinkham, W. H. (1984). Phenotypic variability in siblings with Farber disease. Journal of Pediatrics, 104, 406-409.
    1. Bedia, C., Camacho, L., Abad, J. L., Fabrias, G., & Levade, T. (2010). A simple fluorogenic method for determination of acid ceramidase activity and diagnosis of Farber disease. Journal of Lipid Research, 51, 3542-3547.
    1. van der Beek, N. A., Nelson, I., Froissart, R., Levade, T., Garcia, V., Lacene, E., … Behin, A. (2019). A new case of SMA phenotype without epilepsy due to biallelic variants in ASAH1. European Journal of Human Genetics, 27, 337-339.

"VSports手机版" Publication types

MeSH terms

Associated data